1999, Doctorate, Molecular Biology, Poznan University of Medical Sciences, Poland
1991-1996, Master of Science, Biotechnology, Adam Mickiewicz University, Poznan, Poland
1996-1998, Graduate Student, Department of Biochemistry, RWTH Aachen, Germany
2002-2005, H. Lee Moffitt Cancer Center, Tampa, FL, Immunology Program, Postdoctoral Fellow
1999-2002, RWTH Aachen, Germany, Department of Biochemistry, Postdoctoral Fellow
2021-present, Professor, Immuno-Oncology, City of Hope, Duarte, CA
2015-2021, Associate Professor, Immuno-Oncology, City of Hope, Duarte, CA
2010-2015, Assistant Professor, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, CA
2005-2009, Assistant Research Professor, Cancer Immunotherapeutics & Tumor Immunology, City of Hope, Duarte, CA
Cancers evolved to escape detection by the immune system by co-opting immune cells as a source of growth or angiogenic factors and protection. Targeting signaling specifically in such tumor-associated immune cells has been challenging for pharmacological drugs. We focus on understanding immune cell dysfunction in tumors and translating these findings into novel, precision cancer immunotherapies. Our group developed a platform technology to deliver DNA/RNA drugs into tumor-associated immune cells in vivo. Our synthetic oligonucleotides target the undruggable master regulators at the molecular level, which, as STAT3, NF-kB or certain miRNAs, are nodes of signaling from diverse receptors and kinases. Our two-step immunotherapeutic strategy is to disarm tumor defense systems and activate immune attacks from within using a single DNA/RNA drug.
Over the last years, we have studied the mechanism of crosstalk between cancer cells and tumor-associated myeloid cells in hematologic malignancies and solid tumors such as prostate and kidney cancers. We have also developed a series of oligonucleotide inhibitors optimized for targeting the undruggable intracellular targets such as oncogenic or tolerogenic transcription factors and miRNAs in cancer cells and tumor-associated myeloid cells.
Current studies include:
Targeting Transcriptional Regulators for Immunotherapy of Leukemia and Lymphoma
Tolerogenic Signaling Crosstalk in Solid Tumors
miRNA-Based Oligonucleotides for the Treatment of Cancer and Inflammatory Diseases